Hancock Jaffe Reports Two CoreoGraft Patients Have Reached 30 Day Milestone albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.
Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Reports Two CoreoGraft Patients Have Reached 30 Day Milestone
IRVINE, CA / ACCESSWIRE / December 16, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that two patients who have undergone heart bypass surgeries utilizing HJLI s CoreoGraft have reached the 30-day milestone and are reported to have good cardiac function. The first two CoreoGraft surgeries were completed in late October and early November, respectively.
CoreoGraft patients undergo electrocardiograms and transesophageal echocardiograms at one-month post-surgery, and cardiac catheterization and cardiac computed tomography ( CT ) imaging at three, six, and twelve months post-surgery.
Share:
IRVINE, CA / ACCESSWIRE / December 15, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the final aggregated data for the VenoValve first-in-human trial shows significant improvements in all study endpoints. For the eleven patients in the first-in-human study, reflux (the backwards flow of blood) improved an average of 54%, disease manifestations as measured by a venous clinical severity scores ( VCSS ) improved 56%, and pain, as measured on a visual analog scale ( VAS ), improved 76%, all at one-year post VenoValve surgery when compared to pre-surgery levels. Safety for all patients was assessed as well at one year.
Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Announces Significant Improvements in all Study Endpoints For Final VenoValve First-in-Human Data
IRVINE, CA / ACCESSWIRE / December 15, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the final aggregated data for the VenoValve first-in-human trial shows significant improvements in all study endpoints. For the eleven patients in the first-in-human study, reflux (the backwards flow of blood) improved an average of 54%, disease manifestations as measured by a venous clinical severity scores ( VCSS ) improved 56%, and pain, as measured on a visual analog scale ( VAS ), improved 76%, all at one-year post VenoValve surgery when compared to pre-surgery levels. Safety for all patients was assessed as well at one year.
Hancock Jaffe Announces One Year Follow-up Data on Eleventh VenoValve Patient albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.